<DOC>
	<DOCNO>NCT01168401</DOCNO>
	<brief_summary>Randomized , multi-site , dose-escalation study safety immunogenicity four dosage level Intramuscular ( IM ) Norovirus Bivalent VLP Vaccine adjuvanted monophosphoryl lipid A ( MPL ) aluminum hydroxide ( AlOH ) compare control . Subjects receive two dos , intramuscular ( IM ) injection , 28 day apart . The hypothesis study : - The incidence adverse event vaccination IM Norovirus Bivalent VLP Vaccine similar incidence adverse event IM vaccine include CERVARIX® contains MPL AlOH . - Two dos IM Norovirus Bivalent VLP Vaccine immunogenic one dose . - The post-vaccination serum antibody response , number antibody secrete cell ( ASC ) , include home marker , memory B-cell response direct norovirus antigen increase IM Norovirus Bivalent VLP Vaccine compare control .</brief_summary>
	<brief_title>Bivalent Norovirus Vaccine Study</brief_title>
	<detailed_description />
	<mesh_term>Gastroenteritis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Monophosphoryl lipid A</mesh_term>
	<criteria>Subjects must meet inclusion criterion list : 1 . Signed write informed consent . 2 . Age : Cohort A : 1849 year , inclusive Cohort B : 5064 year , inclusive Cohort C : 6585 year , inclusive 3 . Health Status : Cohort A : In good health determine screen evaluation include vital sign , medical history , physical exam within 45 day administration IM Norovirus Bivalent VLP Vaccine control . Cohorts B C : In good health determine screen evaluation include vital sign , medical history , physical exam within 45 day administration IM Norovirus Bivalent VLP Vaccine control . Any exist medical diagnosis condition must stable base medical history target physical examination . A stable medical condition define : ( A ) Clinically acceptable health outcome specific condition prior 6 month ( B ) No change prescription medication ( ) , dose , frequency prior 3 month . Acceptable change medication : change health care provider insurance company make financial reason long medication class and/or change due improvement disease outcome . 4 . Expressed interest availability fulfill study requirement 5 . Female subject must nonchildbearing potential ( surgically sterile postmenopausal ≥ 12 month ) , childbearing potential ( determined investigator ) must practice abstinence use effective license method birth control ( e.g . oral contraceptive ; diaphragm condom combination contraceptive jelly , cream , foam ; intrauterine contraceptive device , DepoProvera ; skin patch ; vaginal ring cervical cap ) 30 day prior vaccination must agree continue precaution least 60 day last vaccination . A woman eligible monogamous male vasectomy . Male subject must agree father child least 60 day last vaccination practice abstinence use effective method birth control note . 6 . Agrees participate another clinical trial investigational product entire duration study one year last study dose i.e . 393 day . 7 . Agrees storage unused clinical specimen indefinite period time future norovirus research research gastrointestinal pathogen . Subjects meet exclusion criterion baseline exclude study participation . The exclusion criterion : 1 . History follow medical illness : Diabetes Cancer Heart disease ( hospitalization heart attack , arrhythmia , syncope ) Unconsciousness ( single brief `` concussion '' ) Seizures ( febrile seizure child &lt; 5 year old ) Recurrent infection ( 3 hospitalization invasive bacterial infection pneumonia meningitis ) Neuroinflamatory autoimmune disease 2 . Any current illness require daily medication follow : Cohort A : Vitamins , birth control , antihypertensive medication , antihistamine antidepressant medication . The PI consult Central Safety Monitor and/or sponsor clarification medication allowable . Cohorts B C : Vitamins , birth control , antihypertensive medication , antihistamine antidepressant medication current illness require daily medication note inclusion # 3 . The PI consult Central Safety Monitor and/or sponsor clarification medication allowable . 3 . Allergies hypersensitivity component vaccine include MPL AlOH adjuvant . 4 . Any clinically significant abnormality detect physical examination , include : Murmur ( functional murmur ) Focal neurological abnormality Hepatosplenomegaly Lymphadenopathy Jaundice 5 . Hypertension ( BP &gt; 140/90 mm Hg two separate day ) 6 . Any lab abnormality ( per site local laboratory ) , list : Neutrophils ( WBC ) outside normal range ( may repeat outside limit ) Hemoglobin outside normal range ( may repeat outside limit ) Platelet count outside normal range ( may repeat outside limit ) BUN &gt; upper limit normal ( ULN ) ( may repeat outside limit ) Creatinine &gt; upper limit normal ( ULN ) ( may repeat outside limit ) Glucose ( fast random ) outside normal range ( may repeat outside limit ) ALT , AST &gt; upper limit normal ( ULN ) ( may repeat outside limit ) 7 . Positive serology hepatitis C HIV antibody hepatitis B surface antigen . 8 . For woman child bear potential , positive serum pregnancy test within 14 day urine pregnancy test within 24 hour administer either dose IM Norovirus Bivalent VLP Vaccine control . 9 . Nursing mother . 10 . Temperature &gt; 100.4oF symptom acute selflimited illness upper respiratory infection gastroenteritis within 3 day administration IM Norovirus Bivalent VLP Vaccine control . 11 . Previous participation Norovirus vaccine challenge study . 12 . Study site personnel family member . 13 . Significant history psychiatric hospitalization , alcohol abuse , illicit drug use prior 5 year . 14 . Completion investigational vaccine drug study within 28 day administration IM Norovirus Bivalent VLP Vaccine control . 15 . Have history receive immunoglobulin blood product within 3 month prior vaccination study . 16 . Other condition clinical judgment investigator would jeopardize safety right subject participate trial , would render subject unable comply protocol would interfere evaluation vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Prevention acute gastroenteritis due infection noroviruses</keyword>
</DOC>